Assistant Professor, Medicine, Tufts Medical Center

Nephrology

Dana Miskulin practices Nephrology. She has 1 awards "CMS Meaningful Use Stage 1 Certification". Dana Miskulin is a published doctor. She has 51 publications published. The most current publication "Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project." She accepts Medicare payments and is listed with Medicare.gov.

Publications

---

• Comparison of Prescribed and Measured Dialysate Sodium: A Quality Improvement Project.
• Epidemiology of Hypertension in CKD.
• Liver involvement in early autosomal-dominant polycystic Kidney disease.
• Effect of intravenous iron use on hospitalizations in patients undergoing hemodialysis: a comparative effectiveness analysis from the DEcIDE-ESRD study.
• Angiotensin Blockade in Late Autosomal Dominant Polycystic Kidney Disease.
• Blood Pressure in Early Autosomal Dominant Polycystic Kidney Disease.
• Intravenous Iron Exposure and Mortality in Patients on Hemodialysis.
• An instrumental variable approach finds no associated harm or benefit With early dialysis initiation in the United States.
• Health-Related Quality of Life in Patients With Autosomal Dominant Polycystic Kidney Disease and CKD Stages 1-4: A Cross-sectional Study.
• Design of the Blood Pressure in Dialysis Pilot Study.
• Analysis of baseline parameters in the HALT polycystic Kidney disease trials.
• Both patient and facility contribute to achieving the Centers for Medicare and Medicaid Services' pay-for-performance target for dialysis adequacy.
• Effect of bone mineral guideline target achievement on mortality in incident dialysis patients: an analysis of the United Kingdom Renal Registry.
• Peripheral augmentation index and vascular inflammation in autosomal dominant polycystic Kidney disease.
• Nadir hemoglobin levels after discontinuation of epoetin in hemodialysis patients.
• Anemia management in chronic Kidney disease: bursting the hemoglobin bubble.
• Temporal trends in health-related quality of life among hemodialysis patients in the United States.
• Variation in fistula use across dialysis facilities: is it explained by case-mix?
• The HALT polycystic Kidney disease trials: design and implementation.
• Hypertension in hemodialysis patients: the role of antihypertensive medications.
• Disordered mineral Metabolism in hemodialysis patients: an analysis of cumulative effects in the Hemodialysis (HEMO) Study.
• Reducing versus discontinuing erythropoietin at high hemoglobin levels.
• Imperial or empirical measures of dialysis quality?
• Impact of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in a large dialysis network.
• Making an earlier diagnosis of ADPKD: implications for the treatment of Hypertension.
• Hypertension in individuals at risk for autosomal dominant polycystic Kidney disease: to screen or not to screen?
• Demographics and trends in overweight and obesity in patients at time of Kidney transplantation.
• Comorbidity and other factors associated With modality selection in incident dialysis patients: the CHOICE Study. Choices for Healthy Outcomes in Caring for End-Stage ...
• Peritubular capillary basement membrane reduplication in allografts and native Kidney disease: a clinicopathologic study of 278 consecutive renal specimens.
• Comorbidity assessment using the Index of Coexistent Diseases in a multicenter clinical trial.
• Updated comorbidity assessments and outcomes in prevalent hemodialysis patients.
• Age, race, Diabetes, blood pressure, and mortality among hemodialysis patients.
• Inflammation, oxidative stress, and insulin resistance in polycystic Kidney disease.
• Cardiac magnetic resonance assessment of left ventricular mass in autosomal dominant polycystic Kidney disease.
• Short-term reproducibility of ambulatory blood pressure monitoring in autosomal dominant polycystic Kidney disease.
• Key comorbid conditions that are predictive of survival among hemodialysis patients.
• Comorbidity assessment in hemodialysis and peritoneal dialysis using the index of coexistent Disease.
• Comorbidity and its change predict survival in incident dialysis patients.
• Association of nutritional markers With physical and mental health status in prevalent hemodialysis patients from the HEMO study.
• Characterizing comorbidity in dialysis patients: principles of measurement and applications in risk adjustment and patient care.
• A systematic review of sevelamer in ESRD and an analysis of its potential economic impact in Canada and the United States.
• Racial differences in health-related quality of life among hemodialysis patients.
• Predicting 1 year mortality in an outpatient haemodialysis population: a comparison of comorbidity instruments.
• Anemia management and association of race With mortality and hospitalization in a large not-for-profit dialysis organization.
• The influence of age on changes in health-related quality of life over three years in a cohort undergoing hemodialysis.
• Age-related blood pressure patterns and blood pressure variability among hemodialysis patients.
• Which targets in clinical practice guidelines are associated With improved survival in a large dialysis organization?
• Case-mix factors explain the survival advantage of Hispanic and racial minority patients on hemodialysis.
• Computerized decision support for EPO dosing in hemodialysis patients.

Procedures Preformed

---

• Hemodialysis
• Peritoneal Dialysis

Conditions Treated

---

• Acidosis
• Acute Glomerulonephritis
• Acute Kidney Failure
• Alkalosis
• View All

Doctors Specialties

---

• Nephrology

Accepted Insurances

---

Awards

---

• CMS Meaningful Use Stage 1 Certification

Education

---

• Queen's University at Kingston

Hospital

---

• Tufts Medical Center

Drug Facts

---

NPI NUMBER		1922046721
NPPES Provider LastName		MISKULIN
NPPES Provider FirstName		DANA
NPPES Provider ZIPCode		021111552
NPPES Provider State		MA
Specialty Description		Nephrology
Total Claim Count		251.0
Distinct Opioid Count		0.0
Opioid Claim Count		0.0
Percent Opioid Claims		0.0

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1922046721
Last Name Of The Provider	MISKULIN
First Name Of The Provider	DANA
View All

Similar Doctors

---

	Dr. Florian Toegel, MD This Doctor is OpenDoctor Recommended.
	Dr. Eliot C. Heher, MD This Doctor is OpenDoctor Recommended.
	Dr. Khuloud Shukha, MD This Doctor is OpenDoctor Recommended.
	Dr. Anil K. Chandraker, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Gulvahid G. Shaikh, MD
	Dr. Ogo I. Egbuna, MD This Doctor is OpenDoctor Recommended.
	Dr. Robert A. Cohen, MD
	Dr. Charles P. Tifft, MD This Doctor is OpenDoctor Recommended.
	Dr. Dena E. Rifkin, MD
	Dr. Narittaya Varothai, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog